Results' analysis of human papillomavirus determination of 9 810 patients in Liuzhou,Guangxi

doi:10.3969/j.issn.1673-8640.2019.03.013

Abstract

Abstract:

Objective To analyze the results of human papillomavirus （HPV） determination in Liuzhou,Guangxi,and to provide a reference for the prevention and control of HPV infection and HPV vaccine. Methods DNA was extracted. The types of HPV were analyzed by polymerase chain reaction（PCR）. Results The total positive rate was 14.23% （1 396/9 810）. The positive rates of high-risk HPV subtypes and low-risk HPV subtypes were 10.20%（1 001/9 810） and 4.03%（395/9 810）,respectively. Among different age groups,the highest HPV carrying rate was in <20-year-old group （59.46%）. The HPV carrying rate in >60-year-old group was the lowest （0.00%）. There were 1 202 cases carrying 1 type of HPV and 147 cases carrying 2 or more types of HPV in 1 396 positive samples. In mixed infection,double infection was the majority. Conclusions HPV infection has difference in different ages and types. It should select appropriate HPV vaccine in local region.

Key words: Human papillomavirus, Genotyping, Cervical cancer

CLC Number:

R446.5

CAI Pengfei, XU Zehui, WANG Jingren, YAN Tizhen. Results' analysis of human papillomavirus determination of 9 810 patients in Liuzhou,Guangxi[J]. Laboratory Medicine, 2019, 34(3): 246-248.

Figures/Tables 2

References 13

[1]	KANG H S,DE GAGNE J C,SON Y D, et al. Completeness of human papilloma virus vaccination: a systematic review[J]. J Pediatr Nurs, 2018, 39:7-14.
[2]	梁朝霞,陆东阁,葛林,等. 子宫颈感染人乳头瘤病毒的基因分布特点分析[J]. 中国实用医药,2018,13(4):52-53.
[3]	SCHIFFMAN M,CLIFFORD G, BUONAGURO F M.Classification of weakly carcinogenic human papillomavirus types:addressing the limits of epidemiology at the borderline[J]. Infect Agent Cancer, 2009,4:8.
[4]	李巍巍. HPV检测应用于早期宫颈癌筛查中的意义[J]. 中国实用医药,2018,13(4):51-52.
[5]	张雪丹,翁跃颂. HPV DNA分型联合“三阶梯”技术对子宫颈癌前病变诊断及预后判断的价值[J]. 检验医学,2017,32(11):990-993.
[6]	李旭艳. 惠州地区人乳头瘤病毒(HPV)的亚型分布特点及其与年龄的相关性分析[J]. 中国医学创新, 2015, 12(21):102-104.
[7]	刘国强,张朝红,陈建军, 等. 顺德地区妇女人乳头瘤病毒感染类型分布研究[J]. 检验医学与临床,2014,11(19):2726-2727.
[8]	王晓川,孙良起,王欣,等. 洛阳地区201例女性感染HPV及亚型分布特征分析[J]. 河南科技大学学报(医学版), 2014, 32(4):290-292.
[9]	XUE Y,ZHANG W,CHEN M,et al."U" shape of age-specific prevalence of high-risk human papillomavirus infection in women attending hospitals in Shanghai, China[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 145(2) : 214-218.
[10]	黄路遥,许燕燕,娄晓丽,等. 上海市松江区人乳头瘤病毒感染情况分析[J]. 检验医学,2017,32(8):695-699.
[11]	李军,王一羽,南星,等. 陕西省咸阳地区人乳头瘤病毒的基因分型及亚型分布特征[J]. 检验医学,2017,32(3):194-198.
[12]	陈栋,王贵宇,王丰,等. 重庆地区人乳头状瘤感染及其基因型分布特点[J]. 中华医院感染学杂志,2011,21(10):2025-2026.
[13]	徐红,王德录,杜文杰. 人乳头瘤病毒感染的临床实验结果分析[J]. 检验医学,2016,31(9):770-773.

基因型	2016年		2017年
基因型	例数	百分率（%）	例数	百分率（%）
高危型
52	127	23.87	102	21.75
16	81	15.23	50	10.66
58	69	12.97	73	15.57
53	40	7.52	38	8.10
39	33	6.20	36	7.67
18	25	4.70	32	6.82
51	25	4.70	32	6.82
56	23	4.32	25	5.33
66	15	2.82	23	4.91
59	21	3.95	20	4.26
33	23	4.32	9	1.92
35	14	2.63	9	1.92
82	6	1.13	8	1.71
31	12	2.26	6	1.27
68	11	2.07	2	0.43
45	5	0.94	4	0.85
26	2	0.38	0	0.00
低危型
81	30	14.02	44	24.31
44	34	15.89	28	15.47
43	38	17.76	21	11.60
55	29	13.55	21	11.60
61	20	9.35	20	11.05
06	20	9.35	19	10.50
42	20	9.35	13	7.18
11	14	6.54	11	6.08
83	7	3.27	3	1.66
40	2	0.93	1	0.55

基因型	2016年		2017年
基因型	例数	百分率（%）	例数	百分率（%）
高危型
52	127	23.87	102	21.75
16	81	15.23	50	10.66
58	69	12.97	73	15.57
53	40	7.52	38	8.10
39	33	6.20	36	7.67
18	25	4.70	32	6.82
51	25	4.70	32	6.82
56	23	4.32	25	5.33
66	15	2.82	23	4.91
59	21	3.95	20	4.26
33	23	4.32	9	1.92
35	14	2.63	9	1.92
82	6	1.13	8	1.71
31	12	2.26	6	1.27
68	11	2.07	2	0.43
45	5	0.94	4	0.85
26	2	0.38	0	0.00
低危型
81	30	14.02	44	24.31
44	34	15.89	28	15.47
43	38	17.76	21	11.60
55	29	13.55	21	11.60
61	20	9.35	20	11.05
06	20	9.35	19	10.50
42	20	9.35	13	7.18
11	14	6.54	11	6.08
83	7	3.27	3	1.66
40	2	0.93	1	0.55

组别	总例数	检出例数	检出率（%）
<20岁组	37	22	59.46
20~30岁组	2 870	446	15.54
31~40岁组	5 727	753	13.15
41~50岁组	1 112	158	14.20
51~60岁组	50	17	34.00
>60岁组	14	0	0.00
合计	9 810	1 396	14.23

组别	总例数	检出例数	检出率（%）
<20岁组	37	22	59.46
20~30岁组	2 870	446	15.54
31~40岁组	5 727	753	13.15
41~50岁组	1 112	158	14.20
51~60岁组	50	17	34.00
>60岁组	14	0	0.00
合计	9 810	1 396	14.23

[1]	ZHANG Yaxu, CUI Yanwei, LIU Ziyan. Preliminary research for the determination of HPV E6/E7 mRNA by nucleic acid molecular hybridization-flow cytometry [J]. Laboratory Medicine, 2023, 38(1): 46-50.
[2]	SUN Gang, SUN Hui, DU Yandan, LI Yinyan, LI Yingzhi, DONG Zhanzhu, TONG Lijun, PENG Bo. Study on the drug resistance and molecular epidemiological characteristics of MRSA in Hulunbuir [J]. Laboratory Medicine, 2021, 36(6): 600-603.
[3]	LIU Hongqian, SONG Chaohui, LIANG Qiaomi. Determination and quantitation of blood human papillomavirus DNA in healthy subjects [J]. Laboratory Medicine, 2021, 36(11): 1121-1124.
[4]	XUAN Binbin, TAN Meiyu, SUN Hanxiao, SHENG Huiming. Mixed infection status of human papillomavirus,Ureaplasma urealyticum,Chlamydia trachomatis and Neisseria gonorrhoeae in Changning district of Shanghai [J]. Laboratory Medicine, 2020, 35(9): 859-863.
[5]	HOU Jianghou, ZHANG Lingxia, SUN Wenna, LIU Yanhua, YANG Bingfen, SUN Weiguo. Prokaryotic expression and serological verification of antigenic epitopes of human papillomavirus type 16 L1 protein [J]. Laboratory Medicine, 2020, 35(9): 928-932.
[6]	ZHANG Xiaoying. Relationship between the changes of TK1 and ID-1 levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy [J]. Laboratory Medicine, 2020, 35(2): 108-111.
[7]	LIU Cunfen, WANG Yan, YANG Rong, HU Lixiang. Relationship between ESBL genotyping of Escherichia coli and integron in Anning [J]. Laboratory Medicine, 2020, 35(12): 1263-1266.
[8]	SHEN Qionghua. Role of HPV DNA typing in the differential diagnosis of cervical lesions and cervical cancer [J]. Laboratory Medicine, 2019, 34(6): 498-501.
[9]	HUANG Yan, ZHU Xiaoyun, LI Tianying. Role of human papillomavirus DNA assay combined with liquid-based cytology for screening cervical lesion [J]. Laboratory Medicine, 2019, 34(4): 313-317.
[10]	YANG Yang, CHEN Liangyuan, CAO Pengju, CHEN Shaoting, ZHANG Qiuqin, HUANG Chunli, WU Qiumei, CHEN Falin. Analysis of HPV infection and gene subtypes in physical examination women in Fuzhou [J]. Laboratory Medicine, 2019, 34(2): 144-147.
[11]	SUN Yongmei, CHEN Zhaowu, ZHANG Yang, WAN Lingling, LI Ming, DENG Fang. HPV infection status of cervical cancer patients in Anhui and role of HPV determination in monitoring the curative effect of radiotherapy [J]. Laboratory Medicine, 2019, 34(10): 897-900.
[12]	XUAN Qiankun, GUO Jian, WU Wenjuan, LI Guangbo. Clinical application of human papillomavirus E6/E7 mRNA determination [J]. Laboratory Medicine, 2018, 33(7): 640-643.
[13]	HUANG Qunhuan, HONG Ling, TAO Chunlin, HUANG Xuhong. Regulator T cells and cytokines in peripheral blood of cervical cancer patients with different stages [J]. Laboratory Medicine, 2017, 32(9): 769-772.
[14]	HUANG Luyao, XU Yanyan, LOU Xiaoli, CAO Hui, XIA Wanbao, HOU Yanqiang. Human papillomavirus infection in Shanghai Songjiang [J]. Laboratory Medicine, 2017, 32(8): 695-699.
[15]	YAN Xiaohui, LIN Jinduan. Relationship between human papillomavirus infection and the severity of cervical lesions [J]. Laboratory Medicine, 2017, 32(8): 700-703.